Considerations for the design and conduct of externally controlled trials for drug and biological products
This guidance provides recommendations to sponsors and investigators considering the use of externally controlled clinical trials to provide evidence of the safety and effectiveness of a drug product. In an externally controlled trial, outcomes in participants receiving the test treatment according...
Saved in:
Main Authors: | A. S. Motrinchuk, D. Yu. Belousov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Publishing House OKI
2023-12-01
|
Series: | Реальная клиническая практика: данные и доказательства |
Subjects: | |
Online Access: | https://www.myrwd.ru/jour/article/view/51 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of RWD/RWE recommendations and guidelines for 2021. International experience on the example of USA
by: A. Kurylev
Published: (2022-11-01) -
Analyzing FDA's approaches to using electronic health record and medical claims data to support regulatory decision making
by: Ksenia S. Radaeva, et al.
Published: (2023-10-01) -
NICE guidance to working with real-world data
by: A. Sh. Motrinchuk, et al.
Published: (2023-01-01) -
RETRACTED: ESMO Guidance for reporting oncology real-world evidence (GROW)
by: A. Sh. Motrinchuk, et al.
Published: (2024-04-01) -
Current issues related to the off-label use of drugs and their potential solutions
by: K. S. Radaeva, et al.
Published: (2024-04-01)